[2-(Octadecoxymethyl)oxolan-2-yl]methyl 2-(trimethylazaniumyl)ethyl phosphate (BioDeep_00000183745)

   

human metabolite blood metabolite


代谢物信息卡片


2-((Hydroxy-((2-((octadecyloxy)methyl)tetrahydrofuran-2-yl)methoxy)phosphinyl)oxy)-N,N,N-trimethylethylaminium hydroxide inner salt

化学式: C29H60NO6P (549.415803)
中文名称:
谱图信息: 最多检出来源 Homo sapiens(blood) 95%

分子结构信息

SMILES: CCCCCCCCCCCCCCCCCCOCC1(CCCO1)COP(=O)([O-])OCC[N+](C)(C)C
InChI: InChI=1S/C29H60NO6P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-24-33-27-29(22-21-25-34-29)28-36-37(31,32)35-26-23-30(2,3)4/h5-28H2,1-4H3

描述信息

同义名列表

10 个代谢物同义名

2-((Hydroxy-((2-((octadecyloxy)methyl)tetrahydrofuran-2-yl)methoxy)phosphinyl)oxy)-N,N,N-trimethylethylaminium hydroxide inner salt; {2-[(octadecyloxy)methyl]oxolan-2-yl}methyl 2-(trimethylazaniumyl)ethyl phosphoric acid; [2-(Octadecoxymethyl)oxolan-2-yl]methyl 2-(trimethylazaniumyl)ethyl phosphoric acid; {2-[(octadecyloxy)methyl]oxolan-2-yl}methyl 2-(trimethylazaniumyl)ethyl phosphate; {2-[(octadecyloxy)methyl]oxolan-2-yl}methyl 2-(trimethylammonio)ethyl phosphate; [2-(Octadecoxymethyl)oxolan-2-yl]methyl 2-(trimethylazaniumyl)ethyl phosphate; (Tetrahydro-2-(octadecycloxy)methylfuran-2-yl)methoxyphosphocholine; SDZ 266337, (R Isomer); SDZ 266336, (S Isomer); CRC 86-05



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • F Civoli, L W Daniel. Quaternary ammonium analogs of ether lipids inhibit the activation of protein kinase C and the growth of human leukemia cell lines. Cancer chemotherapy and pharmacology. 1998; 42(4):319-26. doi: 10.1007/s002800050824. [PMID: 9744778]
  • J Kovarik, D Chabannes, J F Borel. Immunoregulation and drug treatment in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. International journal of immunopharmacology. 1995 Apr; 17(4):255-63. doi: 10.1016/0192-0561(95)00012-q. [PMID: 7545648]
  • M Lohmeyer, P Workman. The role of intracellular free calcium mobilization in the mechanism of action of antitumour ether lipids SRI 62-834 and ET18-OMe. Biochemical pharmacology. 1993 Jan; 45(1):77-86. doi: 10.1016/0006-2952(93)90379-b. [PMID: 8424826]
  • M Lohmeyer, P Workman. Lack of enantio-selectivity in the in vitro antitumour cytotoxicity and membrane-damaging activity of ether lipid SRI 62-834: further evidence for a non-receptor-mediated mechanism of action. Biochemical pharmacology. 1992 Aug; 44(4):819-23. doi: 10.1016/0006-2952(92)90421-e. [PMID: 1510728]
  • F E Bishop, C Dive, S Freeman, A Gescher. Is metabolism an important arbiter of anticancer activity of ether lipids? Metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites. Cancer chemotherapy and pharmacology. 1992; 31(2):85-92. doi: 10.1007/bf00685092. [PMID: 1451237]
  • C Dive, J V Watson, P Workman. Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells. Cancer research. 1991 Feb; 51(3):799-806. doi: ". [PMID: 1988120]
  • C M Lazenby, M G Thompson, J A Hickman. Elevation of leukemic cell intracellular calcium by the ether lipid SRI 62-834. Cancer research. 1990 Jun; 50(11):3327-30. doi: ". [PMID: 2334926]